2023 World Conference on Lung Cancer (Posters)-P1.23. Amplicon-Based Liquid Biopsy Prospectively Detects More Tissue-Confirmed Guideline-Recommended Biomarkers in Lung Cancer

P1.23. Amplicon-Based Liquid Biopsy Prospectively Detects More Tissue-Confirmed Guideline-Recommended Biomarkers in Lung Cancer - PDF(Slides)

Back to course

Pdf Summary

A study comparing different liquid biopsies with tissue genotyping in patients with metastatic non-squamous non-small cell lung cancer (NSCLC) has shown that an amplicon-based liquid biopsy called LiquidHALLMARK can detect more guideline-recommended biomarkers compared to a hybrid-capture-based test called Guardant360. The study enrolled 120 treatment-naïve NSCLC patients from multiple sites in the USA and Singapore. LiquidHALLMARK detected at least one guideline-recommended biomarker in 72.3% of tissue-positive patients, while Guardant360 detected them in 66.2% of tissue-positive patients. Both tests detected the same G9 biomarkers in 23.6% of tissue-negative or insufficient tissue cases. The overall concordance between LiquidHALLMARK and Guardant360 was 92.1-100%.<br /><br />In NSCLC, actionable biomarkers include specific somatic alterations in genes such as EGFR, ALK, ROS1, RET, BRAF V600E, MET, KRAS G12C, ERBB2/HER2, and NTRK1/2/3. LiquidHALLMARK is able to detect alterations in 80 genes, including 10 fusions in plasma.<br /><br />Tissue genotyping is the gold standard for biomarker testing in NSCLC, but it can fail in 15-40% of patients due to insufficient or unavailable tissue. Liquid biopsy offers a non-invasive alternative for identifying biomarkers in these cases.<br /><br />The study, called LIQUIK-01, is ongoing and aims to demonstrate the usefulness of liquid biopsy in identifying guideline-recommended biomarkers in metastatic non-squamous NSCLC. The interim analysis of the first 120 patients showed that both LiquidHALLMARK and tissue genotyping detected G9 biomarkers in a similar percentage of tissue-conﬁrmed patients. The individual concordance between LiquidHALLMARK and tissue genotyping ranged from 93.1% to 100%.<br /><br />Overall, this study suggests that amplicon-based liquid biopsy can be a valuable tool for detecting biomarkers in lung cancer patients, especially when tissue genotyping is not feasible. LiquidHALLMARK showed promising results in identifying guideline-recommended biomarkers, potentially enabling more personalized treatment approaches for NSCLC patients.

Asset Subtitle

Richa Dawar

Meta Tag

Speaker Richa Dawar

Topic Pathology & Biomarkers: Liquid Based Biomarkers

Keywords

liquid biopsy

tissue genotyping

metastatic NSCLC

LiquidHALLMARK

Guardant360

biomarkers

amplicon-based

hybrid-capture-based

EGFR

personalized treatment